Back

Mavacamten eligibility in an Irish hypertrophic cardiomyopathy cohort

19 May 2025 (09:00 - 10:00)
Organised by: Logo
Congress Presentation Part of: ePosters in myocardial disease - hypertrophic cardiomyopathy (3) Hypertrophic Cardiomyopathy HFA Premium Access Heart Failure 2025 Heart Failure Association (HFA)

About the speaker

Photo
Mr Paul Kopp

Stony Brook (United States of America)

7 More presentations in this session

Presentation thumbnail
Usefulness of implantable loop recorders in patients with hypertrophic cardiomyopathy
Doctor M. Figueiredo (Barreiro, PT)
Abstract Slides Video
Presentation thumbnail
Medical education significantly improves the recognition of red flags of transthyretin cardiac amyloidosis
Doctor C. Rohani-Montez (London, GB)
Abstract Slides Video
Presentation thumbnail
Reduction of >100 mmHg left ventricular outflow tract gradients in obstructive hypertrophic cardiomyopathy during mavacamten treatment already after one week of treatment
Doctor R. Sepp (Szeged, HU)
Abstract Slides Video
Presentation thumbnail
Temporal changes in echocardiographic parameters of diastolic dysfunction in obstructive hypertrophic cardiomyopathy during mavacamten treatment
Doctor H. Takacs (Szeged, HU)
Abstract Slides Video
Presentation thumbnail
Phenotypic expression and prognostic determinants in TPM1-associated hypertrophic cardiomyopathy: insights from a tertiary center cohort
Doctor C. Gregorio (Lisbon, PT)
Abstract Slides Video

Access the full session

Session thumbnail
ePosters in myocardial disease - hypertrophic cardiomyopathy (3)

The Event

Event poster

Heart Failure 2025

19 May 2025 09:00 CET
You may be interested in
thumbnail
Congress Presentation
Mavacamten in a real-world hypertrophic cardiomyopathy population: how many may be eligible?
thumbnail
Congress Presentation
Mavacamten in a real-world hypertrophic cardiomyopathy population: how many may be eligible?
thumbnail
Congress Presentation
Hemodynamic and symptomatic response in real-world patients with hypertrophic obstructive cardiomyopathy and myosin inhibitor therapy

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources